This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoon, D. S. B. Articles by Irie, R. F. Search for Related Content PubMed PubMed Citation Articles by Hoon, D. S. B. Articles by Irie, R. F.

Modulation of Human Melanoma Cells by Interleukin-4 and in Combination with -Interferon or -Tumor Necrosis Factor¹

Division of Surgical Oncology, John Wayne Cancer Clinic, University of California at Los Angeles School of Medicine, Los Angeles, California 90024

Immune cytokines have been shown to play important roles in regulating immune cell functions. Interleukin-4 (IL4), originally described as a B-cell growth factor, is known to activate and differentiate other immune cells. IL4 has been given as an immunotherapeutic to tumor-bearing hosts. In this report, we set out to determine whether IL4 can directly modulate growth and expression of surface antigens on human melanoma cells. The effect of recombinant IL4 alone and in combination with recombinant -interferon (IFN) or recombinant -tumor necrosis factor (TNF) on melanoma cell lines was examined. IL4 significantly inhibited cell growth of all cell lines examined at 100–500 units/ml; but a dose-dependent differential response to individual cell lines occurred. The effect of IL4 was augmented by combination with IFN or TNF. Melanoma-associated ganglioside antigens (GM3, GD3, GM2, GD2) and human leukocyte antigen class I and DR on the cell surface of melanoma cells were assessed by flow cytometry and/or a radiometric binding assay. IL4, IFN, or TNF alone enhanced human leukocyte antigen class I, DR, and ß₂-microglobulin antigen expression. IL4 alone and in combination with IFN or TNF increased the GM3/GD3 ratio expression. GD2 was enhanced significantly by IL4, IFN, and TNF. Pretreatment of melanoma with IL4 or with other cytokines prior to stimulation with peripheral blood lymphocytes significantly enhanced mixed lymphocyte tumor reaction activity as compared with non-treated melanoma used as stimulators. These studies demonstrate that IL4 alone or in combination with IFN and TNF can modulate melanoma growth activity and surface antigen expression to a more differentiated and immunogenic phenotype.

¹ This study was supported by Grant CA 12582 awarded by the National Cancer Institute, United States Department of Health and Human Services.

² To whom requests for reprints should be addressed, at Division of Surgical Oncology, CHS 54-140, University of California at Los Angeles School of Medicine, Los Angeles, CA 90024.

Received 10/ 8/90. Accepted 2/ 5/91.

This article has been cited by other articles:

				B. D. Beseth, R. B. Cameron, P. Leland, L. You, F. Varricchio, R. J. Kreitman, R. A. Maki, D. M. Jablons, S. R. Husain, and R. K. Puri Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts Ann. Thorac. Surg., August 1, 2004; 78(2): 436 - 443. [Abstract] [Full Text] [PDF]

				H. Takeuchi, A. Fujimoto, M. Tanaka, T. Yamano, E. Hsueh, and D. S. B. Hoon CCL21 Chemokine Regulates Chemokine Receptor CCR7 Bearing Malignant Melanoma Cells Clin. Cancer Res., April 1, 2004; 10(7): 2351 - 2358. [Abstract] [Full Text] [PDF]

				B. Taback, A. D. Chan, C. T. Kuo, P. J. Bostick, H.-J. Wang, A. E. Giuliano, and D. S. B. Hoon Detection of Occult Metastatic Breast Cancer Cells in Blood by a Multimolecular Marker Assay: Correlation with Clinical Stage of Disease Cancer Res., December 1, 2001; 61(24): 8845 - 8850. [Abstract] [Full Text] [PDF]

				R. Essner, Y. Huynh, T. Nguyen, D. L. Morton, and D. S. B. Hoon FUNCTIONAL INTERLEUKIN 4 RECEPTOR AND INTERLEUKIN 2 RECEPTOR COMMON {gamma}-CHAIN ON HUMAN NON-SMALL CELL LUNG CANCERS: NOVEL TARGETS FOR IMMUNE THERAPY J. Thorac. Cardiovasc. Surg., January 1, 2000; 119(1): 10 - 20. [Abstract] [Full Text] [PDF]